Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) gains approval from the Human Research Ethics Committee to expand its phase I/II trial of R327 to treat UTIs
- The trial is assessing faster administration rates with Scientia Clinical Research facilitating the expansion as a participating institution
- RCE will administer its R327 lead product to 16 participants within a GP or an acute patient setting as a broad-spectrum anti-infective for simple, complicated, and recurring UTIs
- The company aims to commence its phase two trial in the second half of 2023
- RCE shares closed today 0.81 per cent higher at 62 cents
Recce Pharmaceuticals (RCE) has obtained approval from the Human Research Ethics Committee to expand its trial using R327 to treat urinary tract infections (UTIs).
The trial is assessing R327 at faster administration rates, with Scientia Clinical Research included in the expansion as a participating institution.
Scientia Clinical Research is an FDA-audited world-class clinical trials facility, with offices in Sydney and New South Wales that specialise in first-in-human and first-in-patient studies.
The company plans to administer its R327 lead product to 16 participants within a GP or an acute patient setting as a broad-spectrum anti-infective for simple, complicated, and recurring UTIs.
“We are pleased to expand our phase I/II UTI studies with Scientia Clinical Research (NSW) joining present dosing at CMAX (SA),” RCE CEO James Graham said.
“This now multistate study expects to expedite our clinical trial progress and address the global health threats posed by UTIs and Urosepsis.”
Recce announced it hopes to commence its phase II trial in the second half of 2023.
RCE shares closed today 0.81 per cent higher at 62 cents.
